Wieke Jakob, Jurcic Christina, Kaczorowski Adam, Böning Sarah, Kirchner Martina, Schwab Constantin, Schütz Viktoria, Hohenfellner Markus, Duensing Anette, Stenzinger Albrecht, Duensing Stefan
Molecular Urooncology, Department of Urology, University Hospital Heidelberg, Heidelberg, Germany.
Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Front Oncol. 2025 Apr 25;15:1551077. doi: 10.3389/fonc.2025.1551077. eCollection 2025.
Renal cell carcinoma (RCC) is characterized by a high degree of genomic but also functional intratumoral heterogeneity (ITH). Mutations in , chromatin remodeling genes such as and genes that regulate the PI3K/AKT/mTOR pathway have been identified as recurrent drivers despite genomic ITH. Whether and to what extent these mutations shape functional ITH including the formation of spatial niches is incompletely understood. Herein, we analyze the correlation between mutational drivers and their functional proxies in a spatially defined manner.
A total of 23 RCCs were analyzed by panel next-generation sequencing followed by immunohistochemistry for five functional proxies for key genetic alterations including the expression of CD31, GLUT1, phospho-mTOR S2448, H3K36me3 and Ki-67. Antibody stainings were scored semiquantitatively in the tumor periphery and the tumor center.
Unexpectedly, the presence of a mutation was not found to correlate with its functional proxies including the expression of CD31/microvessel density or the expression of the glucose transporter GLUT1. Likewise, there was no correlation between the presence of activating mutations in genes of the PI3K/AKT/mTOR pathway and the expression of activated phospho-mTOR S2448. Furthermore, mutations in the methyltransferase gene were not found to correlate with the expression level of its downstream target H3K36me3. Lastly, there was no correlation between the expression of the proliferation marker Ki-67 and the number of driver mutations.
This proof-of-concept study adds genotype-phenotype heterogeneity as additional layer of complexity to the known genomic and functional ITH in RCC.
肾细胞癌(RCC)的特征是具有高度的基因组内肿瘤异质性(ITH),同时也存在功能上的ITH。尽管存在基因组ITH,但染色质重塑基因(如 )和调节PI3K/AKT/mTOR通路的基因中的突变已被确定为常见驱动因素。这些突变是否以及在多大程度上塑造了包括空间生态位形成在内的功能ITH尚不完全清楚。在此,我们以空间定义的方式分析突变驱动因素与其功能替代指标之间的相关性。
对23例RCC进行二代测序分析,随后进行免疫组织化学检测,以检测包括CD31、GLUT1、磷酸化mTOR S2448、H3K36me3和Ki-67表达在内的关键基因改变的五个功能替代指标。在肿瘤周边和肿瘤中心对抗体染色进行半定量评分。
出乎意料的是,未发现 突变的存在与其功能替代指标相关,包括CD31/微血管密度的表达或葡萄糖转运蛋白GLUT1的表达。同样,PI3K/AKT/mTOR通路基因中的激活突变与激活的磷酸化mTOR S2448的表达之间也没有相关性。此外,未发现甲基转移酶基因 中的突变与其下游靶点H3K36me3的表达水平相关。最后,增殖标志物Ki-67的表达与驱动突变的数量之间没有相关性。
这项概念验证研究在RCC已知的基因组和功能ITH基础上,增加了基因型-表型异质性这一复杂性层面。